IMMUNIC, INC. 8-K

What Happened
Immunic, Inc. (IMUX) filed an 8-K reporting that its stockholders approved a reverse stock split at a ratio selectable between 1-for-10 and 1-for-30 at a special meeting on April 14, 2026. The Board selected a 1-for-10 reverse stock split and the Company filed a Certificate of Amendment with the Delaware Secretary of State on April 22, 2026 to effect the change. The Company expects the New Common Stock (CUSIP 4525EP200) to begin trading on the Nasdaq Capital Market under the existing symbol “IMUX” on a post-split basis when the market opens on April 27, 2026.

Key Details

• Reverse split ratio: 1-for-10 (board-selected after stockholder approval of a 1-for-10 to 1-for-30 range).
• Outstanding shares before/after: approximately 136 million pre-split → ~13.6 million post-split.
• Corporate filings/dates: Certificate of Amendment filed April 22, 2026; press release issued April 23, 2026.
• Effect on equity instruments: per-share exercise prices and number of shares for outstanding stock options, restricted stock units (RSUs) and warrants will be proportionally adjusted. No fractional shares will be issued—fractions will be aggregated, sold by the transfer agent, and holders will receive cash in lieu of fractional shares.

Why It Matters
A reverse stock split reduces the number of outstanding shares and increases the per-share price proportionally; it does not change the Company’s market capitalization or the number of authorized shares. For investors, this means your holdings will be consolidated at a 10-to-1 ratio and option/RSU/warrant terms will be adjusted to reflect the split. Fractional-share holders will receive cash payments in lieu of fractional shares. Trading will continue under the same ticker (IMUX) after the split is implemented.